New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer

The chemokine receptor CXCR4 is overexpressed and functional in colorectal cancer. To investigate the role of CXCR4 antagonism in potentiating colon cancer standard therapy, the new peptide CXCR4 antagonist Peptide R (Pep R) was employed. Human colon cancer HCT116 xenograft-bearing mice were treated...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Crescenzo D’Alterio, Antonella Zannetti, Anna Maria Trotta, Caterina Ieranò, Maria Napolitano, Giuseppina Rea, Adelaide Greco, Piera Maiolino, Sandra Albanese, Giosuè Scognamiglio, Fabiana Tatangelo, Salvatore Tafuto, Luigi Portella, Sara Santagata, Guglielmo Nasti, Alessandro Ottaiano, Roberto Pacelli, Paolo Delrio, Gerardo Botti, Stefania Scala
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI AG 2020-07-01
Серии:Cancers
Предметы:
colorectal cancer
CXCR4/CXCL12 axis
EMT epithelial-to-mesenchymal transition
radiotherapy
chemotherapy
chemoresistance
Online-ссылка:https://www.mdpi.com/2072-6694/12/7/1952
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы